
## Toshiyuki Kamoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6093950/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. International Journal of Clinical Oncology, 2017, 22, 166-173.	2.2	45
2	Rapid detection of candidate metastatic foci in the orthotopic inoculation model of androgen-sensitive prostate cancer cells introduced with green fluorescent protein. Prostate, 2000, 45, 335-340.	2.3	26
3	Differential prognostic factors in low―and highâ€burden deÂnovo metastatic hormoneâ€sensitive prostate cancer patients. Cancer Science, 2021, 112, 1524-1533.	3.9	19
4	Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression. Human Cell, 2016, 29, 22-29.	2.7	16
5	Caveolin-1 and -2 regulate cell motility in castration-resistant prostate cancer. Research and Reports in Urology, 2018, Volume 10, 135-144.	1.0	15
6	Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression. Cancer Genomics and Proteomics, 2015, 12, 391-6.	2.0	15
7	Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 346.e1-346.e8.	1.6	15
8	Surgical procedures for benign prostatic hyperplasia: A nationwide survey in Japan, 2014 update. International Journal of Urology, 2017, 24, 476-477.	1.0	14
9	Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis. International Journal of Molecular Sciences, 2018, 19, 3708.	4.1	14
10	Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers. International Journal of Molecular Sciences, 2020, 21, 2663.	4.1	14
11	The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients. BMC Cancer, 2019, 19, 156.	2.6	13
12	Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 6164-6173.	7.0	10
13	Myopericytoma in urinary bladder: a case report. Journal of Medical Case Reports, 2017, 11, 46.	0.8	9
14	Feasibility of laparoscopic adrenalectomy for metastatic adrenal tumors in selected patients: a retrospective multicenter study of Japanese populations. International Journal of Clinical Oncology, 2020, 25, 126-134.	2.2	9
15	Novel metastatic burdenâ€stratified risk model in de novo metastatic hormoneâ€sensitive prostate cancer. Cancer Science, 2021, 112, 3616-3626.	3.9	8
16	JUA clinical guidelines for benign prostatic hyperplasia. International Journal of Urology, 2011, 18, e1.	1.0	5
17	Dysregulated HAI-2 Plays an Important Role in Renal Cell Carcinoma Bone Metastasis through Ligand-Dependent MET Phosphorylation. Cancers, 2018, 10, 190.	3.7	5
18	Expression of protease activating receptor-2 (PAR-2) is positively correlated with the recurrence of non-muscle invasive bladder cancer: an immunohistochemical analysis. Research and Reports in Urology, 2019, Volume 11, 97-104.	1.0	5

Тознічикі Камото

#	Article	IF	CITATIONS
19	Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells. Life Sciences, 2021, 278, 119554.	4.3	5
20	Ct Evaluation of Acupuncture Needles Inserted into Sacral Foramina. Acupuncture in Medicine, 2016, 34, 20-26.	1.0	4
21	Efficacy of combined androgen blockade therapy in patients with metastatic hormoneâ€sensitive prostate cancer stratified by tumor burden. International Journal of Urology, 2022, , .	1.0	4
22	Prostateâ€specific antigen density during dutasteride treatment for 1Âyear predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study). International Journal of Urology, 2021, 28, 849-854.	1.0	3
23	Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy. JNCI Cancer Spectrum, 2022, 6, pkac001.	2.9	3
24	Presurgical treatment with axitinib in renal cell carcinoma patients with venous extension. International Cancer Conference Journal, 2015, 4, 216-220.	0.5	2
25	Safe Resection of Renal Cell Carcinoma with Liver Invasion Using Liver Hanging Technique Supported by Preoperative Portal Vein Embolization. Case Reports in Urology, 2018, 2018, 1-7.	0.3	2
26	En bloc removal of a large leiomyosarcoma arising from the inferior vena cava using retroperitoneal laparoscopic dissection of posterior vessels followed by cavectomy in a thoracoabdominal approach. Urology Case Reports, 2019, 26, 100984.	0.3	2
27	Surveillance of urachal abscess in the Kyushu–Okinawa area of Japan. International Journal of Urology, 2021, 28, 1008-1011.	1.0	2
28	Narrative review of local prostate and metastasis-directed radiotherapy in the treatment of metastatic prostate cancer. Japanese Journal of Clinical Oncology, 2022, 52, 633-641.	1.3	2
29	A novel case presenting with an unusual ureteral diverticular lesion similar to adenomyomatous hyperplasia of the gallbladder. Pathology International, 2016, 66, 169-173.	1.3	0
30	Left renal mass presenting uncommon pattern of extension in a patient with intestinal malrotation. International Cancer Conference Journal, 2017, 6, 88-91.	0.5	0
31	Surgical intervention for renal cell carcinoma with inferior vena cava extension combined with laparoscopic procedure. Research and Reports in Urology, 2017, Volume 9, 107-112.	1.0	0
32	A case of von Hippel–Lindau disease with renal cell carcinoma treated by partial nephrectomy with pre- and post-surgical axitinib therapy. Urology Case Reports, 2021, 40, 101925.	0.3	0
33	polymorphisms and their association with prostate cancer risk in Japanese men. Journal of Preventive Medicine and Hygiene, 2021, 62, E489-E495.	0.9	0
34	Evaluation of tumor genomic variants in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide: Protocol of a phase 4 study (CUARTET) Journal of Clinical Oncology, 2022, 40, TPS196-TPS196.	1.6	0